Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin -: Clinical pathophysiology and natural history of β-cell dysfunction and insulin resistance

被引:190
作者
Mauvais-Jarvis, F
Sobngwi, E
Porcher, R
Riveline, JP
Kevorkian, JP
Vaisse, C
Charpentier, G
Guillausseau, PJ
Vexiau, P
Gautier, JF
机构
[1] Saint Louis Hosp, Dept Endocrinol & Diabet, Paris, France
[2] Univ Paris 07, Sch Med, Paris, France
[3] Saint Louis Hosp, Dept Med Biostat, Paris, France
[4] Sud Francilien Hosp, Dept Diabet & Metab Dis, Corbeil Essonnes, France
[5] Lariboisiere Hosp, Dept Internal Med B, Paris, France
[6] Univ Calif San Francisco, Dept Med, Diabet Res Ctr, San Francisco, CA USA
关键词
D O I
10.2337/diabetes.53.3.645
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonautoimmune ketosis-prone diabetic syndromes are increasingly frequent in nonwhite populations. We have characterized a cohort of patients of sub-Saharan African origin who had ketosis-prone type 2 diabetes (n = 111), type I diabetes (n = 21), and type 2 diabetes (n = 88) and were admitted to a hospital for management of uncontrolled diabetes. We compared epidemiological, clinical, and metabolic features at diabetes onset and measured insulin secretion (glucagon-stimulated C-peptide) and insulin action (short intravenous insulin tolerance test) during a 10-year follow-up. Ketosis-prone type 2 diabetes shows a strong male predominance, stronger family history, higher age and BMI, and more severe metabolic decompensation than type 1 diabetes. In ketosis-prone type 2 diabetes, discontinuation of insulin therapy with development of remission of insulin dependence is achieved in 76% of patients (noninsulin dependent), whereas only 24% of patients remain insulin dependent. During evolution, ketosisprone type 2 diabetes exhibit specific beta-cell dysfunction features that distinguish it from type 1 and type 2 diabetes. The clinical course of non-insulin-dependent ketosis-prone type 2 diabetes is characterized by ketotic relapses followed or not by a new remission. Progressive hyperglycemia precedes and is a strong risk factor for ketotic relapses (hazard ratio 38). The probability for non-insulin-dependent ketosis-prone type 2 diabetes to relapse is 90% within 10 years, of whom similar to50% will become definitively insulin dependent. Insulin sensitivity is decreased in equal proportion in both ketosis-prone type 2 diabetes and type 2 diabetes, but improves significantly in non-insulin-dependent ketosis-prone type 2 diabetes, only after correction of hyperglycemia. In conclusion, ketosis-prone type 2 diabetes can be distinguished from type I diabetes and classical type 2 diabetes by specific features of clinical pathophysiology and also by the natural history of P-cell dysfunction and insulin resistance reflecting a propensity to glucose toxicity.
引用
收藏
页码:645 / 653
页数:9
相关论文
共 39 条
[1]  
Ahren B, 1985, Diabet Med, V2, P262
[2]  
Aizawa T, 1997, DIABETIC MED, V14, P989
[3]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[4]  
2-S
[5]   Insulin secretion, insulin sensitivity and diabetes in black children [J].
Arslanian, S ;
Danadian, K .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (05) :194-199
[6]   New profiles of diabetic ketoacidosis -: Type 1 vs type 2 diabetes and the effect of ethnicity [J].
Balasubramanyam, A ;
Zern, JW ;
Hyman, DJ ;
Pavlik, V .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (19) :2317-2322
[7]   GAD ANTIBODY NEGATIVE NIDDM IN ADULT BLACK SUBJECTS WITH DIABETIC-KETOACIDOSIS AND INCREASED FREQUENCY OF HUMAN-LEUKOCYTE ANTIGEN DR3 AND DR4 - FLATBUSH DIABETES [J].
BANERJI, MA ;
CHAIKEN, RL ;
HUEY, H ;
TUOMI, T ;
NORIN, AJ ;
MACKAY, IR ;
ROWLEY, MJ ;
ZIMMET, PZ ;
LEBOVITZ, HE .
DIABETES, 1994, 43 (06) :741-745
[8]   IMMUNOLOGY AND DIABETES WORKSHOP - REPORT ON THE 3RD INTERNATIONAL (STAGE-3) WORKSHOP ON THE STANDARDIZATION OF CYTOPLASMIC ISLET CELL ANTIBODIES HELD IN NEW-YORK, NEW-YORK, OCTOBER 1987 [J].
BOITARD, C ;
BONIFACIO, E ;
BOTTAZZO, GF ;
GLEICHMANN, H ;
MOLENAAR, J .
DIABETOLOGIA, 1988, 31 (07) :451-452
[9]  
Boutin P, 1999, DIABETOLOGIA, V42, P380
[10]  
EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360